PRESS RELEASEDecember 16th, 2015
Leucadia Therapeutics and the Methuselah Foundation Announce a Partnership to Cure Alzheimer’s Disease
Leucadia Therapeutics LLC, a biotechnology company focused on treating and preventing Alzheimer’s disease, and Methuselah Foundation, a public charity incentivizing innovation in regenerative medicine, today announced a joint partnership to develop a novel therapeutic strategy to treat Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia in the elderly, affecting over 5 million people in the USA. Affected individuals have difficulty creating new memories, and problems with language, mood and reasoning. As the disease progresses, patients become withdrawn and bodily functions decline, leading to death within 3-9 years of diagnosis. No current drugs or treatments slow or halt the relentless progression of Alzheimer’s disease.
Leucadia Therapeutics LLC was founded with the idea of taking a new approach to curing Alzheimer’s disease, using patent-pending technology to correct the cause of the disease rather than its effects. The company will use this investment to accelerate development of novel therapy with the goal of beginning clinical trials in 2018. Leucadia Therapeutics Chief Scientific Officer, Douglas Ethell, Ph.D., said, “This is an exciting event for LT as it frees us from fundraising and allows us to focus our efforts on getting into the clinic as soon as possible.”
Under this agreement, the Methuselah Foundation has made an equity investment in Leucadia Therapeutics LLC. Over the next 3-5 years, Leucadia will develop and test a novel therapeutic device to treat the underlying cause of Alzheimer’s disease.
Will you join us?You can find out how to become a foundation supporter at Mfoundation.org.
We thank you for your support now and in the future!